DMP 323
DMP 323 Basic information
- Product Name:
- DMP 323
- Synonyms:
-
- DMP 323
- (4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
- 2H-1,3-Diazepin-2-one, hexahydro-5,6-dihydroxy-1,3-bis[[4-(hydroxymethyl)phenyl]methyl]-4,7-bis(phenylmethyl)-, (4R,5S,6S,7R)-
- JCR 424
- JCR424
- JCR-424
- CAS:
- 151867-81-1
- MF:
- C35H38N2O5
- MW:
- 566.69
- Mol File:
- 151867-81-1.mol
DMP 323 Chemical Properties
- Boiling point:
- 798.6±60.0 °C(Predicted)
- Density
- 1.294±0.06 g/cm3(Predicted)
- pka
- 14.08±0.70(Predicted)
DMP 323 Usage And Synthesis
Uses
DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, effective against both HIV type 1 and type 2. Designed using structural information and database searching, it competitively inhibits the cleavage of both peptide and HIV-1 gag polyprotein substrates. DMP 323 shows comparable potency to other highly effective HIV protease inhibitors like A-80987 and Ro-31-8959. Importantly, its efficacy against HIV protease remains unaffected by human plasma or serum, suggesting low affinity for plasma proteins. Furthermore, DMP 323 demonstrates minimal inhibition of various mammalian proteases at concentrations much higher than those needed for HIV protease inhibition, highlighting its specificity for viral targets[1].
Definition
ChEBI: A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively.
References
[1] Potency and Selectivity of Inhibition of Human Immunodeficiency Virus Protease by a Small Nonpeptide Cyclic Urea, DMP 323